Roble Belko & Company’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-157
| Closed | -$29K | – | 451 |
|
|
2025
Q4 | $29K | Hold |
157
| – | – | ﹤0.01% | 241 |
|
|
2025
Q3 | $24K | Hold |
157
| – | – | ﹤0.01% | 222 |
|
|
2025
Q2 | $22K | Hold |
157
| – | – | ﹤0.01% | 228 |
|
|
2025
Q1 | $23K | Hold |
157
| – | – | ﹤0.01% | 213 |
|
|
2024
Q4 | $21K | Hold |
157
| – | – | ﹤0.01% | 213 |
|
|
2024
Q3 | $24K | Hold |
157
| – | – | ﹤0.01% | 197 |
|
|
2024
Q2 | $24K | Hold |
157
| – | – | ﹤0.01% | 201 |
|
|
2024
Q1 | $21K | Hold |
157
| – | – | ﹤0.01% | 210 |
|
|
2023
Q4 | $21K | Hold |
157
| – | – | ﹤0.01% | 198 |
|
|
2023
Q3 | $21K | Hold |
157
| – | – | ﹤0.01% | 178 |
|
|
2023
Q2 | $22K | Hold |
157
| – | – | ﹤0.01% | 183 |
|
|
2023
Q1 | $22K | Sell |
157
-260
| -62% | -$35K | ﹤0.01% | 194 |
|
|
2022
Q4 | $57K | Buy |
417
+157
| +60% | +$19.7K | 0.01% | 148 |
|
|
2022
Q3 | $29K | Hold |
260
| – | – | 0.01% | 178 |
|
|
2022
Q2 | $34K | Hold |
260
| – | – | 0.01% | 172 |
|
|
2022
Q1 | $34K | Hold |
260
| – | – | 0.01% | 183 |
|
|
2021
Q4 | $30K | Hold |
260
| – | – | 0.01% | 183 |
|
|
2021
Q3 | $31K | Hold |
260
| – | – | 0.01% | 171 |
|
|
2021
Q2 | $31K | Hold |
260
| – | – | 0.01% | 183 |
|
|
2021
Q1 | $26K | Hold |
260
| – | – | 0.01% | 185 |
|
|
2020
Q4 | $26K | Hold |
260
| – | – | 0.01% | 173 |
|
|
2020
Q3 | $28K | Hold |
260
| – | – | 0.01% | 165 |
|
|
2020
Q2 | $28K | Hold |
260
| – | – | 0.01% | 173 |
|
|
2020
Q1 | $23K | Hold |
260
| – | – | 0.01% | 179 |
|
|
2019
Q4 | $26K | Hold |
260
| – | – | 0.01% | 188 |
|
|
2019
Q3 | $23K | Hold |
260
| – | – | 0.01% | 190 |
|
|
2019
Q2 | $21K | Hold |
260
| – | – | 0.01% | 196 |
|
|
2019
Q1 | $21K | Hold |
260
| – | – | 0.01% | 163 |
|
|
2018
Q4 | $20K | Hold |
260
| – | – | 0.01% | 154 |
|
|
2018
Q3 | $21K | Hold |
260
| – | – | 0.01% | 157 |
|
|
2018
Q2 | $18K | Hold |
260
| – | – | 0.01% | 172 |
|
|
2018
Q1 | $18K | Hold |
260
| – | – | 0.01% | 183 |
|
|
2017
Q4 | $18K | Hold |
260
| – | – | 0.01% | 175 |
|
|
2017
Q3 | $18K | Hold |
260
| – | – | 0.01% | 145 |
|
|
2017
Q2 | $18K | Hold |
260
| – | – | 0.01% | 144 |
|
|
2017
Q1 | $16K | Hold |
260
| – | – | 0.01% | 155 |
|
|
2016
Q4 | $14K | Hold |
260
| – | – | 0.01% | 177 |
|
|
2016
Q3 | $17K | Hold |
260
| – | – | 0.01% | 173 |
|
|
2016
Q2 | $16K | Hold |
260
| – | – | 0.01% | 165 |
|
|
2016
Q1 | $15K | Hold |
260
| – | – | 0.01% | 143 |
|
|
2015
Q4 | $18K | Hold |
260
| – | – | 0.01% | 127 |
|
|
2015
Q3 | $17K | Hold |
260
| – | – | 0.01% | 122 |
|
|
2015
Q2 | $17K | Hold |
260
| – | – | 0.01% | 134 |
|
|
2015
Q1 | $18K | Buy |
+260
| New | +$18.1K | 0.01% | 137 |
|
Other funds holding AZN
IA
Roble Belko & Company's AZN Position: Q1 2026 in Review
Roble Belko & Company sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 157 shares — an estimated $29K sold.
Roble Belko & Company first reported a position in AZN in Q1 2015 and held it in 44 quarters. The position peaked at $57K in Q4 2022. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Roble Belko & Company reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Roble Belko & Company sold 157 AstraZeneca shares in Q1 2026, an estimated $29K.
- Roble Belko & Company first reported a position in AstraZeneca in Q1 2015 and held it in 44 quarters.
- Roble Belko & Company's AstraZeneca position peaked at $57K in Q4 2022.
- 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Roble Belko & Company's 13F filing for Q1 2026, filed 16 Apr 2026.